Primary Site >> Colorectal Cancer
Gene >> FCGR2A
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
|
Ref: Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor. PMID: 1638551 |
Ref: Prothymosin alpha 1 effects in vitro on chemotaxis, cytotoxicity and oxidative response of neutrophils from melanoma, colorectal and breast tumor patients. PMID: 9568546 |
Ref: Irinotecan-induced immune thrombocytopenia. PMID: 9636839 |
Ref: Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. PMID: 18983497 |
Ref: Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. PMID: 22117530 |
Ref: Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. PMID: 22486600 |
Ref: Predicting skin toxicity according to EGFR polymorphisms in patients with colorectal cancer receiving antibody against EGFR. PMID: 24222141 |
Ref: Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. PMID: 27179112 Ref: FCGR, Cetuximab, and Colorectal Cancer Survival-Letter. PMID: 27697992 |
Ref: Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis. PMID: 27897268 Ref: Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis. PMID: 28243990 |
Ref: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. PMID: 28719596 Ref: Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. PMID: 30318772 |